Cencora in the news

Cencora's Chief Accounting Officer sold 986 shares of company stock for over $303 each under a pre-arranged trading plan.

Cencora's growth is driven by specialty pharmaceutical distribution and GLP drug volumes, supported by operational efficiency and disciplined capital management amidst a challenging healthcare market.

Cencora's buy rating is reaffirmed due to strong fundamentals, including an investment-grade rating, positive operating cash flow, and improved operating margin, despite market underperformance and sector-specific risks.

Cencora Inc's SVP & Chief Accounting Officer sold shares, contributing to a trend of insider selling, while the stock is fairly valued and institutional investors show positive sentiment.

Cencora achieved strong Q3 FY2026 results with double-digit operating income and EPS growth, raising its full-year EPS guidance due to robust performance in its U.S. and International Healthcare Solutions segments, especially in specialty pharmaceuticals.

Cencora director Robert E. Sanchez was granted 275 restricted stock units that vest in one year.

Cencora will release its Q4 Fiscal 2026 earnings on November 4, 2026, with a conference call scheduled for the same day.

Cencora's stock trades at USD 309.05 as it approaches its November 4 fiscal Q4 earnings release, with raised full-year adjusted EPS guidance and a brokerage consensus target of USD 370.85.

Cencora appointed former Ryder System CEO Robert E. Sanchez as an independent director, enhancing its board's expertise in logistics and supply chain for its pharmaceutical distribution business.

Cencora appointed Robert E. Sanchez to its board, and despite recent stock fluctuations, analysts consider the company 16% undervalued with a fair value of $369, though it faces risks from biosimilar pressure and contract shifts.

Cencora Inc.'s stock experienced a strong trading day, outperforming its competitors.

Cencora director Robert E. Sanchez indirectly holds 197 shares through a revocable trust.

Cencora announced the release date and time for its Fourth Quarter Fiscal 2026 earnings and details for the accompanying conference call.

Cencora Inc. stock increased by 3.2% but is deemed slightly overvalued, with a strong GF Score™ yet notable insider selling.

Cencora's stock increased by 3.0% today, driven by strong Q3 financial results, including an increase in revenue and EPS guidance, substantial share repurchases, and positive sentiment across the pharmaceutical distribution sector.

Cencora's stock price dropped 2.39% to $300.25, underperforming the overall market, and is 20.47% below its 52-week high.

Cencora's stock saw a slight increase after-hours, while the company appointed a new independent director and launched a new cell and gene therapy service.

Cencora Inc.'s stock outperformed its competitors even after experiencing losses on the day.

Cencora appointed Robert Sanchez, former Ryder System Inc. CEO, to its board of directors.

Cencora's stock price dropped slightly on September 28, 2026, while the company announced the appointment of Robert E. Sanchez to its board of directors.